The Form 144 is an advance notice of intent to sell; the actual sale may or may not occur. Given Goldsmith's history of routine RSU-based sales, this filing carries no material signal. Monitor for a subsequent Form 4 to confirm execution. No change to investment thesis.
Price Chart
Executive Summary
Director and Officer Mark A. Goldsmith filed a Form 144 indicating intent to sell 9,772 shares of Revolution Medicines common stock, valued at approximately $1.5M based on the filing date price. The shares were acquired via restricted stock unit grants in 2023-2025. This is a routine sale consistent with Goldsmith's prior selling pattern (132,871 shares sold in the past three months) and does not signal a change in company outlook.
Key Facts
- Mark A. Goldsmith (Officer/Director) filed Form 144 to sell 9,772 shares of RVMD common stock.
- Estimated value of proposed sale: ~$1,503,617.64 (based on ~$153.86/share).
- Shares to be sold were acquired from RSU grants on 03/01/2023 (3,488 shares), 03/01/2024 (3,018 shares), and 03/01/2025 (3,266 shares).
- Goldsmith sold 12,871 shares on 03/17/2026 and 120,000 shares on 04/15/2026, totaling 132,871 shares in the prior three months.
- Company market cap is ~$32.7B; analyst consensus is 96% bullish (26 analysts: 11 Strong Buy, 15 Buy).
Financial Impact
Not specified
Risk Factors
- Insider selling could be misinterpreted as negative signal by the market, though the pattern is routine.
- Additional unannounced sales by other insiders could accumulate.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001246842-26-000002 |
| Document: 0001246842-26-000002-index.html | 0001246842-26-000002 |
| Document: 0001246842-26-000002.txt | 0001246842-26-000002 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 17d ago | Insider Cluster | $204.86 $190.95 | ▼ −6.79% | ▼ −7.61% | $206.29 (+0.70%) |
Sep 14, 2026 17d ago | Insider Cluster | $204.86 $192.86 | ▼ −5.86% | ▼ −7.98% | $206.29 (+0.70%) |
Aug 26, 2026 5w ago | 8-K | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 26, 2026 5w ago | Press Release | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 25, 2026 5w ago | Insider Cluster | $211.38 $209.87 | ▼ −0.71% | ▼ −0.18% | $206.29 (−2.41%) |
Jul 2, 2026 13w ago | Press Release | $189.24 $191.13 | ▲ +1.00% | ▲ +0.07% | $206.29 (+9.01%) |
Jul 1, 2026 13w ago | Insider Cluster | $187.51 $190.46 | ▲ +1.57% | ▲ +1.31% | $206.29 (+10.02%) |
Jun 22, 2026 14w ago | 8-K | $165.81 $192.62 | ▲ +16.17% | ▲ +16.62% | $206.29 (+24.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access